Skip to Main Content

WASHINGTON — It’s less than a week old, but a shadowy new pharma advocacy group is already launching diatribes against advocates for lower drug prices, blasting pharmacy middlemen and defending even sky-high list prices for prescription drugs.

The new group, the Alliance to Protect Medical Innovation, says its goal is to “help educate policymakers and the public about medical breakthroughs developed by the biopharmaceutical industry.” An “About Us” section on its website describes it as a 501(c)(4) nonprofit.


It’s not clear who funds the group, or even who is running the group’s day-to-day operations. The group’s website includes no information on funding nor a staff directory, and the group did not respond to immediate request for comment from STAT. It’s not clear exactly when the group launched, but its first link to a news story is dated Sept. 26. An associated Twitter account sent its first tweet on Sept. 28.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!